Search research articles
Contact Us
Filters
Showing results (141-150 of 304) with videos related to
Page
of 31
Sort By:
Expert Review of Molecular Diagnostics
|
March 17, 2011
Integrating biomarkers in clinical trials
Marc Buyse, Stefan Michiels, Daniel J Sargent, et al.
Cancer Chemotherapy and Pharmacology
|
October 24, 2018
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer
Robert J Mayer, Howard S Hochster, Steven J Cohen, et al.
The Oncologist
|
May 14, 2014
Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care
Axel Grothey, Suzanne George, Eric van Cutsem, et al.
Cancer Research
|
January 25, 2003
Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer
Thomas Mueller, Wieland Voigt, Heike Simon, et al.
Cancer Management and Research
|
May 12, 2017
Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment
Juan Marcos González, Sarika Ogale, Robert Morlock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse
Sumithra J Mandrekar, Ming-Wen An, Jeffrey Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Randomized phase II trials: inevitable or inadvisable?
Hui K Gan, Axel Grothey, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2008
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)
Axel Grothey, Mary M Sugrue, David M Purdie, et al.
Contemporary Clinical Trials Communications
|
December 25, 2019
Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials
Ming-Wen An, Jun Tang, Axel Grothey, et al.
Cancer
|
July 30, 2011
Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE)
Blase N Polite, Amy Sing, Daniel J Sargent, et al.
Page
of 31
Search research articles
Search
Showing results (141-150 of 304) with videos related to
Sort By:
Page
of 31
Expert Review of Molecular Diagnostics
|
March 17, 2011
Integrating biomarkers in clinical trials
Marc Buyse, Stefan Michiels, Daniel J Sargent, et al.
Cancer Chemotherapy and Pharmacology
|
October 24, 2018
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer
Robert J Mayer, Howard S Hochster, Steven J Cohen, et al.
The Oncologist
|
May 14, 2014
Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care
Axel Grothey, Suzanne George, Eric van Cutsem, et al.
Cancer Research
|
January 25, 2003
Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer
Thomas Mueller, Wieland Voigt, Heike Simon, et al.
Cancer Management and Research
|
May 12, 2017
Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment
Juan Marcos González, Sarika Ogale, Robert Morlock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse
Sumithra J Mandrekar, Ming-Wen An, Jeffrey Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Randomized phase II trials: inevitable or inadvisable?
Hui K Gan, Axel Grothey, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2008
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)
Axel Grothey, Mary M Sugrue, David M Purdie, et al.
Contemporary Clinical Trials Communications
|
December 25, 2019
Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials
Ming-Wen An, Jun Tang, Axel Grothey, et al.
Cancer
|
July 30, 2011
Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE)
Blase N Polite, Amy Sing, Daniel J Sargent, et al.
Page
of 31